Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian Patients

Wafaa El-Zefzafy; Hanan Eltokhy; Nagwa Abd El-Ghaffar Mohamed; Zakia Abu-Zahab

doi:10.3889/oamjms.2015.021

Authors

Wafaa El-Zefzafy Faculty of Medicine for Girls Al-Azhar University, Tropical Medicine, Cairo
Hanan Eltokhy Faculty of Medicine for Girls Al-Azhar University, Internal Medicine, Cairo
Nagwa Abd El-Ghaffar Mohamed Department of Clinical and Chemical Pathology, National Research Center, AL-Tahreer Street, AL-Dokki, Giza, Cairo 12622
Zakia Abu-Zahab Faculty of Medicine for Girls Al-Azhar University, Clinical Pathology, Cairo

DOI:

https://doi.org/10.3889/oamjms.2015.021

Keywords:

Cytokeratin-18, viral hepatitis, HCC, Î±-fetoprotein, tumor marker

Abstract

BACKGROUND: Hepatitis C virus is one of the most common etiologic agents of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma in which there is continuous inflammation and regeneration of hepatocytes.Cytokeratin-18 (CK18) has been suggested to play an important role in tumorigenesis of epithelial cancers.

AIM: Estimation of CK18 serum levels in patients with chronic viral hepatitis C (CHCV) and hepatocellular carcinoma (HCC) and find the relationship between their levels, the severity of the disease and the development of HCC.

METHODS: We measured serum levels of CK18 in 60 Egyptian patients (30 with CHCV & 30 with HCC) and 30 healthy controls.

RESULTS: Patients with HCC had highly significant increased CK18 levels compared with CHCV patients, healthy controls. Cytokeratin-18 among the three classes of Child-Pugh classification show highly significant gradual increase from child A to C. Furthermore, In HCC there were positive correlations between CK18 and with RBCs, ESR, and AFP.

CONCLUSION: CK18 is a sensitive indicator of the severity of liver disease. Patients with CHCV infection can be followed up by measurement of its serum level which can predict the development of HCC. The combination of AFP and CK18 increased the sensitivity of detection for HCC.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Yousra A Mohamoud, Ghina R Mumtaz, Suzanne Riome, DeWolfe Miller and Laith J Abu-Raddad. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis, BMC. Infectious Diseases. 2013; 13:288. DOI: https://doi.org/10.1186/1471-2334-13-288

Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg. 2002; 67: 436â€“442. DOI: https://doi.org/10.4269/ajtmh.2002.67.436

Luedde T, Schwabe RF. NF-ÎºB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108-18. DOI: https://doi.org/10.1038/nrgastro.2010.213

El-Serag HB, Marrero JA, Rudolph L Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752â€“1763. DOI: https://doi.org/10.1053/j.gastro.2008.02.090

Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. DOI: https://doi.org/10.1371/journal.pmed.1001624

Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013; 29: 285â€“292. DOI: https://doi.org/10.1097/MOG.0b013e32835ff1cf

Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst. Rev. 2012; 9:CD002799. DOI: https://doi.org/10.1002/14651858.CD002799.pub2

Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1(4):593-598. DOI: https://doi.org/10.3892/mco.2013.119

Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW. New consensus nomenclature for mammalian keratins. J Cell Biol. 2006;174 (2): 169â€“174. DOI: https://doi.org/10.1083/jcb.200603161

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897-904. DOI: https://doi.org/10.1158/1078-0432.CCR-04-0378

Oshima RG. Apoptosis and keratin intermediate filaments. Cell Death Differ. 2002; 9: 486â€“92 DOI: https://doi.org/10.1038/sj.cdd.4400988

Linder S. Cytokeratin markers come of age. Tumour Biol. 2007; 28: 189â€“95. DOI: https://doi.org/10.1159/000107582

Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, Hamilton G. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg. 2009;13(11):2020-6. DOI: https://doi.org/10.1007/s11605-009-0992-6

Bantel H, LÃ¼gering A, Heidemann J. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004; 40: 1078â€“87.

Qin X, Lin L, Mo Z, Lv H, Gao Y, Tan A, Yang X, Li S, Zhao J. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic males from the Fangchenggang Area Male Health and Examination Survey. Int J Biol Markers. 2011;26(1):65-7. DOI: https://doi.org/10.5301/JBM.2011.6364

Sumer S, Demir AK, KÃ¶lgelier S, Inkaya AC, Arpaci A, Demir LS, Ural O. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepatitis Monthly. 2013; 13 (6): e10106. DOI: https://doi.org/10.5812/hepatmon.10106

Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013;5(9):479-86. DOI: https://doi.org/10.4254/wjh.v5.i9.479

Bantel H, LÃ¼gering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40(5):1078-87. DOI: https://doi.org/10.1002/hep.20411

Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205â€“219. DOI: https://doi.org/10.1016/S0092-8674(04)00046-7

Madersbacher S, Gregor N, Theyer G, Steiner G, Marberger M. TPS is a useful epithelial proliferation and tumor marker. J Urol. 1992; 147:A911.

Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma. Journal of Clinical Gastroenterology. 2013; 47 Suppl:S2-6. DOI: https://doi.org/10.1097/MCG.0b013e3182872f29

Avunduk C. Tumors of the liver and biliary system. The Manual of Gastroenterology, Diagnosis and therap. 2008 ; 455-8. 4th edition Philadelphia,Lippincott William,Wilkins. PA1960USA. https://books.google.com.eg/books.

Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006; 107(9): 2212-22. DOI: https://doi.org/10.1002/cncr.22242

Friedman LS, Martin P, Munoz SJ. Laboratory methods for evaluation of the liver disease. In Zakim D,Boyer TD,eds Hepatology: A Texextbook of Liver Disaes, 4th edn. Philadelphia: Saunders, 2002:661-708.

Gonzalez-Quintela A, Mallo N, Mella C, Campos J, Perez LF, Lopez-Rodriguez R, Tome S, Otero E. Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int. 2006;26(10):1217-24. DOI: https://doi.org/10.1111/j.1478-3231.2006.01380.x

Collazos J, Genolla J, Ruibal A. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis. Digestion. 1992; 53: 157â€“61. DOI: https://doi.org/10.1159/000200991

Tu DG, Wang ST, Chang TT, Chiu NT, Yao WJ. The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma. Cancer. 1999;85(5):1039-43. DOI: https://doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1039::AID-CNCR5>3.0.CO;2-B

Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012; 56: 267-275. DOI: https://doi.org/10.1016/j.jhep.2011.07.007

Patel M, Shariff MI, Ladep NG, Thillainayagam AV, Thomas HC, Khan SA, Taylor-Robinson SD. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012 ;18(2):335-42. DOI: https://doi.org/10.1111/j.1365-2753.2010.01599.x

Gallo V, Cerutti E, Riberi A, Re M, Petrino R, Pecchio F. Alpha-fetoprotein and tissue polypeptide antigen in non neoplastic hepatic disorder. J Nucl Med Allied Sci. 1989; 33(3): 89â€“93.

Kao CH, Gu CJ, Wang SJ. Tissue polypeptide specific antigen in hepatitis B carriers. Anticancer Res. 1994; 14:2817â€“8.

Abdel Haleem H, Zayed N, Abdel Hafez H, Fouad A, Akl M, Hassan M, Hammam O, Morsy A, Saleh A, Seyam M, Zakaria Z, Zakaria S. Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C. Arab J Gastroenterol. 2013;14(2):68-72. DOI: https://doi.org/10.1016/j.ajg.2013.03.004